Updates From the 7th World Symposium Task Force

Chapter 1: Episode 1: Patient Perspectives in Pulmonary Hypertension

5 chapters
1.00 credits
60 minutes
Play All
CME/CE
ReachMD Healthcare Image
Media formats available:
Details
Program chapters
Presenters
Comments
  • Overview

    The 7th World Symposium Task Force on Pulmonary Hypertension focused on the standard of care, best practices, and emerging clinical data in the treatment of pulmonary hypertension (PH). For the first time, the 2024 Symposium started with patients’ perspectives, acknowledging the respect and importance that should be given to patients’ priorities. The translational aspects of modern pulmonary vascular research were highlighted, as were transplantation, bridging and support technologies, palliative care, management of pregnant women with PH, specificities of pediatric care, and the benefits of emerging multimodality imaging techniques and novel technologies. Tune in to get the details and improve care for your patients today! 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Faculty: 

    Eric D. Austin, MD, MSCI
    Associate Professor of Pediatrics
    Vanderbilt University
    Nashville, TN 

    Dr. Austin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research support: National Institute of Health, Cardiovascular Medical Research Foundation
    Consulting fees: Scientific advisory board for Merck

    Hilary M. DuBrock, MD 
    Critical Care Specialist 
    Mayo Clinic 
    Rochester, MN  

    Dr. DuBrock has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research support: Bayer
    Consulting fees: Janssen, Merck

    H. James Ford, MD  
    Director, Pulmonary Hypertension Program 
    University of North Carolina at Chapel Hill 
    Chapel Hill, NC  

    Dr. Ford has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research support: Gossamer, Janssen, Liquidia, Merck, United Therapeutics 

    Gustavo A. Heresi, MD, MS 
    Section Head, Pulmonary Vascular Disease
    Respiratory Institute
    Cleveland, OH 

    Dr. Heresi has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research support: Bayer HealthCare
    Consulting fees: Bayer HealthCare, Johnson & Johnson 

    Gergely Meszaros, JD, MSc  
    Patient Advocate 
    ERN-LUNG 
    Frankfurt, Germany  

    No relevant relationships reported. 

    Lucilla Piccari, MD, PhD
    Director, Pulmonary Vascular Research Program of SEPAR
    Hospital del Mar
    Barcelona, Spain  

    Dr. Piccari has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research support: Ferrer, Janssen
    Consulting fees: Ferrer, Gossamer Bio, Janssen, Liquidia, MSD Spain, United Therapeutics 

    Ioana R. Preston, MD 
    Associate Professor of Medicine
    Tufts University School of Medicine
    Boston, MA 

    Dr. Preston has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research support: Acceleron/Merck, Actelion/Janssen, Keros, Liquidia, Respira, United Therapeutics
    Consulting fees: Acceleron/Merck, Actelion/Janssen, Aerovate, Gossamer, Keros, Liquidia, Respira, United Therapeutics

    Oksana A. Shlobin, MD
    Medical Director, Pulmonary Hypertension Program
    University of Virginia School of Medicine
    Falls Church, VA 

    Dr. Shlobin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting fees: Aerami, Bayer, Enzyvant, Gossamer, Insmed, Janssen, Merck, United Therapeutics 

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has nothing to disclose.
    • Prerna Poojary, PhD, has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Apply the 7th World Symposium updates to pulmonary hypertension (PH) risk assessment and patient management
    • Implement best practices addressing social determinants of health in the PH population
    • Evaluate best strategies for managing care and adverse events while maximizing therapy for patients with pulmonary hypertension 
  • Target Audience

    This activity has been designed to meet the educational needs of cardiologists and pulmonologists, as well as all other healthcare providers involved in managing patients with pulmonary hypertension.  

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

     

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.  

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 10/11/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity 

     

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.10 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-114-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care. 

  • Commercial Support

    This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, and Merck Sharp & Dohme LLC. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited  
    Reproduction of this materialis not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Register

We're glad to see you're enjoying MedEd On The Go…
but how about a more personalized experience?

Register for free